-
1.发明申请COMPOSITIONS COMPRISING CITRULLINE AND LEUCINE AND THEIR USE IN THE TREATMENT OF DIABETES AND METABOLIC SYNDROME 有权包含CITRULLINE和LEUCINE的组合物及其在治疗糖尿病和代谢综合征中的应用公开(公告)号：US20160235699A1
公开(公告)日：2016-08-18
申请号：US15027580
申请日：2014-10-03
Applicant: NESTEC S.A.
Inventor： Christophe Moinard , Gabrielle Ventura , Denis Breuille , Christian Darimont-Nicolau , Luc Cynober
IPC: A61K31/198 , A61K31/17 , A61K45/06
CPC classification number: A61K31/198 , A61K31/16 , A61K31/17 , A61K45/06 , A61K2300/00
Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.
Abstract translation: 本公开一般涉及包含瓜氨酸和亮氨酸或其代谢物的组合物，其包括例如协同量的瓜氨酸和亮氨酸。 此类组合物可用于治疗代谢综合征，高血糖症和/或高胰岛素血症的方法。
-
2.发明申请ESCHERICHIA COLI AS A MARKER FOR HYPERTRIGLYCERIDEMIA 审中-公开ESCHERICHIA COLI作为HYPERTRIGLYCERIDEMIA的标记公开(公告)号：US20160168627A1
公开(公告)日：2016-06-16
申请号：US14902810
申请日：2014-06-24
Applicant: NESTEC S.A.
Inventor： Chieh Jason Chou , Christian Darimont-Nicolau , Mathieu Membrez
IPC: C12Q1/68 , G01N33/569
CPC classification number: C12Q1/689 , C12Q1/10 , C12Q2600/118 , G01N33/56916 , G01N33/92 , G01N2800/044 , G01N2800/50
Abstract: The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.
Abstract translation: 本发明涉及通过定量受试者的胃肠系统中肠杆菌（例如大肠杆菌）的量来预测受试者发生高甘油三酯血症的风险。 本发明还涉及治疗具有高甘油三酯血症或具有该病症风险的受试者。
-
公开(公告)号：US11419838B2
公开(公告)日：2022-08-23
申请号：US15892078
申请日：2018-02-08
Applicant: NESTEC S.A.
Inventor： Christophe Moinard , Gabrielle Ventura , Denis Breuille , Christian Darimont-Nicolau , Luc Cynober
IPC: A61K31/198 , A61K31/16 , A61K31/17 , A61K45/06
Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.
-
公开(公告)号：US09962415B2
公开(公告)日：2018-05-08
申请号：US14787817
申请日：2014-05-01
Applicant: NESTEC S.A.
Inventor： Christian Darimont-Nicolau , Bernard Berger , Enea Rezzonico , Catherine Ngom-Bru , Melissa LePage
IPC: A01N63/00 , A61K35/747 , A61K8/99 , C12Q1/04 , A61Q19/06 , C12Q1/06 , A23L33/135
CPC classification number: A61K35/747 , A23L33/135 , A23V2002/00 , A23Y2220/73 , A61K8/99 , A61K2800/92 , A61Q19/06 , C12Q1/04 , C12Q1/06 , G01N2333/33 , G01N2800/044 , A23V2200/3204 , A23V2200/332
Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
-
Patent Agency Ranking
5.发明申请LACHNOSPIRACEAE IN THE GUT MICROBIOTA AND ASSOCIATION WITH BODY WEIGHT 有权乳腺微生物中的LACHNOSPIRACEAE和身体重量的关联公开(公告)号：US20160089404A1
公开(公告)日：2016-03-31
申请号：US14787817
申请日：2014-05-01
Applicant: NESTEC S.A.
Inventor： Christian Darimont-Nicolau , Bernard Berger , Enea Rezzonico , Catherine Ngom-Bru , Melissa LePage
IPC: A61K35/747 , C12Q1/06
CPC classification number: A61K35/747 , A23L33/135 , A23V2002/00 , A23Y2220/73 , A61K8/99 , A61K2800/92 , A61Q19/06 , C12Q1/04 , C12Q1/06 , G01N2333/33 , G01N2800/044 , A23V2200/3204 , A23V2200/332
Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
Abstract translation: 本发明涉及用于调节受试者，优选人的肠道微生物群组成的方法和方法。 特别地，本发明提供一种能够减少受试者的肠道微生物群组合物中Lachnospiraceae的比例的试剂，该试剂可用于促进体重减轻或预防受试者，优选肥胖或超重受试者的体重增加。 作为由本发明提供并用于本发明的试剂，特别优选鼠李糖乳杆菌CGMCC1.3724。
-
公开(公告)号：US09913818B2
公开(公告)日：2018-03-13
申请号：US15027580
申请日：2014-10-03
Applicant: NESTEC S.A.
Inventor： Christophe Moinard , Gabrielle Ventura , Denis Breuille , Christian Darimont-Nicolau , Luc Cynober
IPC: A61K31/198 , A61K31/16 , A61K31/17 , A61K45/06
CPC classification number: A61K31/198 , A61K31/16 , A61K31/17 , A61K45/06 , A61K2300/00
Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.
-
7.发明申请公开(公告)号：US20180338942A1
公开(公告)日：2018-11-29
申请号：US15892078
申请日：2018-02-08
Applicant: NESTEC S.A.
Inventor： Christophe Moinard , Gabrielle Ventura , Denis Breuille , Christian Darimont-Nicolau , Luc Cynober
IPC: A61K31/198 , A61K45/06 , A61K31/17 , A61K31/16
Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.
-
公开(公告)号：US20150045425A1
公开(公告)日：2015-02-12
申请号：US14465807
申请日：2014-08-21
Applicant: NESTEC S.A.
Inventor： Mohamed Nabil Bosco , Christian Darimont-Nicolau , Jalil Benyacoub
IPC: A61K31/365 , A61K36/23 , A23L1/30 , A61K36/29
CPC classification number: A61K31/365 , A23L33/10 , A61K36/23 , A61K36/29 , A61K2300/00
Abstract: The present invention relates to the field of metabolic disorders and aims to identify natural compounds that can be used effectively in this field. In particular, the present invention provides a composition comprising at least one peltatin for use in the treatment or prevention of metabolic disorders or risk factors thereof.
Abstract translation: 本发明涉及代谢紊乱领域，其目的在于鉴定可在该领域有效使用的天然化合物。 特别地，本发明提供了包含至少一种用于治疗或预防代谢紊乱或其危险因素的皮肤素的组合物。
-
公开(公告)号：US20150057344A1
公开(公告)日：2015-02-26
申请号：US14465801
申请日：2014-08-21
Applicant: NESTEC S.A.
Inventor： Mohamed Nabil Bosco , Christian Darimont-Nicolau , Jalil Benyacoub
CPC classification number: A61K31/365 , A23V2002/00 , A61K8/4973 , A61K36/23 , A61K36/29 , A61Q19/00 , A61K2300/00
Abstract: The present invention generally relates to health benefits of natural compounds. In particular, the present invention relates peltatins, a group of natural compounds that can be used to treat, prevent or alleviate chronic inflammatory disorders. For example, the present invention concerns a composition comprising at least one peltatin for use in the treatment or prevention of chronic inflammatory disorders.
Abstract translation: 本发明一般涉及天然化合物的健康益处。 特别地，本发明涉及可以用于治疗，预防或缓解慢性炎症性疾病的帕尔汀，一组天然化合物。 例如，本发明涉及包含至少一种用于治疗或预防慢性炎症性疾病的皮肤素的组合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.011 seconds)
